Thalys Medical Technology Group Corporation (SHA:603716)

Market Cap	3.48B +69.5%
Revenue (ttm)	971.32M -39.8%
Net Income	-210.48M
EPS	-1.04
Shares Out	214.11M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,525,078
Open	15.92
Previous Close	16.24
Day's Range	15.70 - 16.75
52-Week Range	11.65 - 38.12
Beta	0.37
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About SHA:603716

Thalys Medical Technology Group Corporation provides medical integrated operation and management services in China. It offers automated immunofluorescence analyzer; coagulation reagent; COVID-19 test kit; line blot1 fully automated immunoblotting instrument; and flow products. The company also provides automated coagulation analyzer; automated immunoassay system; automated biochemical analysis system; automated chemiluminescence immunoassay system; and blood analyzer. The company was formerly known as Thalys Medical Technology Inc. and changed ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 1,246
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603716

Financial Performance

In 2025, SHA:603716's revenue was 1.08 billion, a decrease of -40.52% compared to the previous year's 1.81 billion. Losses were -207.28 million, -0.93% less than in 2024.